Cyclooxygenase-2 mediates dialysate-Lnduced alterations of the peritoneal membrane

Journal of the American Society of Nephrology

Volumn 20, Issue 3, 2009, Pages 582-592

  Aroeira, Luiz S ^a,b   Lara Pezzi, Enrique ^a,c   Loureiro, Jesús ^a,c   Aguilera, Abelardo ^a,d   Ramírez Huesca, Marta ^a,c   González Mateo, Guadalupe ^a,b   Pérez Lozano, M Luisa ^a,c   Albar Vizcaíno, Patricia ^a,c   Bajo, M Auxiliadora ^a,b   Peso, Gloria Del ^a,b   Sánchez Tomero, Jose Antonio ^a,d   Jiménez Heffernan, José Antonio ^a,e   Selgas, Rafael ^a,b   López Cabrera, Manuel ^a,c,d,f  

^a Lnstituto Reina Sofía de Investigaciones Nefrológicas   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Centro de Biología Molecular   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; COLLAGEN TYPE 1; CYCLOOXYGENASE 2; FIBRONECTIN; GLUCOSE; INTERLEUKIN 1BETA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PERITONEAL DIALYSIS FLUID; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE; DIALYSIS MEMBRANE; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; FIBROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MALE; MEMBRANE DAMAGE; MESENCHYME CELL; MESOTHELIUM CELL; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; ULTRAFILTRATION; UPREGULATION;

EID: 62149120618     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008020211     Document Type: Article

References (35)

1. Krediet RT: The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 55: 341-356, 1999
2. Aroeira LS, Aguilera A, Sanchez-Tomero JA, Bajo MA, del Peso G, Jimenez-Heffernan JA, Selgas R, Lopez-Cabrera M: Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: Pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 18: 2004-2013, 2007
3. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13: 470-479, 2002
4. Aroeira LS, Aguilera A, Selgas R, Ramirez-Huesca M, Perez-Lozano ML, Cirugeda A, Bajo MA, del Peso G, Sanchez-Tomero JA, Jimenez- Heffernan JA, Lopez-Cabrera M: Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: Role of vascular endothelial growth factor. Am J Kidney Dis 46: 938-948, 2005
5. Jimenez-Heffernan JA, Aguilera A, Aroeira LS, Lara-Pezzi E, Bajo MA, del Peso G, Ramirez M, Gamallo C, Sanchez-Tomero JA, Alvarez V, Lopez-Cabrera M, Selgas R: Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch 444: 247-256, 2004
6. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez- Jimenez C, Jimenez-Heffernan JA, Aguilera A, Sanchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C, Sanchez-Madrid F, Lopez-Cabrera M: Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 348: 403-413, 2003
7. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, Kelly MM: Transient overexpression of TGF-beta1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 16: 425-436, 2005
8. Yang AH, Chen JY, Lin JK: Myofibroblastic conversion of mesothelial cells. Kidney Int 63: 1530-1539, 2003
9. Turini ME, DuBois RN: Cyclooxygenase-2: A therapeutic target. Annu Rev Med 53: 35-57, 2002
10. Gately S, Li WW: Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy. Semin Oncol 31: 2-11, 2004
11. Khanapure SP, Garvey DS, Janero DR, Letts LG: Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem 7: 311-340, 2007
12. Bonner JC, Rice AB, Ingram JL, Moomaw CR, Nyska A, Bradbury A, Sessoms AR, Chulada PC, Morgan DL, Zeldin DC, Langenbach R: Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol 161: 459-470, 2002
13. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC: Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929-939, 2002
14. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters- Golden M: Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 95: 1861-1868, 1995
15. Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M: JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology 125: 556-571, 2003
16. Steinhauer HB, Schollmeyer P: Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. Kidney Int 29: 584-590, 1986
17. Zemel D, Koomen GC, Hart AA, ten Berge IJ, Struijk DG, Krediet RT: Relationship of TNF-alpha, interleukin-6, and prostaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 122: 686-696, 1993
18. Shanmugam N, Kim YS, Lanting L, Natarajan R: Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 278: 34834-34844, 2003
19. Sitter T, Haslinger B, Mandl S, Fricke H, Held E, Sellmayer A: High glucose increases prostaglandin E2 synthesis in human peritoneal mesothelial cells: role of hyperosmolarity. J Am Soc Nephrol 9: 2005- 2012, 1998
20. Douma CE, de Waart DR, Zemel D, Struijk DG, Krediet RT: Prostaglandin inhibition by intraperitoneal indomethacin has no effect on peritoneal permeability during stable CARD. Nephrol Dial Transplant 16: 803-808, 2001
21. Zemel D, Struijk DG, Dinkla C, Stolk LM, ten Berge IJ, Krediet RT: Effects of intraperitoneal cyclooxygenase inhibition on inflammatory mediators in dialysate and peritoneal membrane characteristics during peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 126: 204-215, 1995
22. Liu H, Peng Y, Liu F, Li J, Chen X, Liu Y, Zhang H: A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-be- ta1 synthesis and matrix production in human peritoneal mesothelial cells. Cell Biol Int 31: 508-515, 2007
23. Ferguson MW, O'Kane S: Scar-free healing: From embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 359: 839-850, 2004
24. Martin P, D'Souza D, Martin J, Grose R, Cooper L, Maki R, McKercher SR: Wound healing in the PU.1 null mouse: Tissue repair is not dependent on inflammatory cells. Curr Biol 13:1122-1128, 2003
25. Martin P, Leibovich SJ: Inflammatory cells during wound repair: The good, the bad and the ugly. Trends Cell Biol 15: 599-607, 2005
26. Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC: Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 35: 644-652, 2000
27. Lai KN, Tang SC, Leung JC: Mediators of inflammation and fibrosis. Pent Dial Int 27[Suppl 2]: S65-S71, 2007
28. Giatromanolaki A, Kotsiou S, Koukourakis Ml, Sivridis E: Angiogenic factor expression in hepatic cirrhosis. Mediators Inflamm 2007: 67187, 2007
29. Tunyogi-Csapo M, Koreny T, Vermes C, Galante JO, Jacobs JJ, Giant TT: Role of fibroblasts and fibroblast-derived growth factors in periprosthetic angiogenesis. J Orthop Res 25: 1378-1388, 2007
30. Harris RC, Breyer MD: Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol 1: 236-245, 2006
31. Garcia-Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P: Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Pent Dial Int 27[Suppl 2]: S205-S209, 2007
32. Selgas R, Fernandez-Reyes MJ, Bosque E, Bajo MA, Borrego F, Jimenez C, Del Peso G, De Alvaro F: Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 23: 64-73, 1994
33. Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT: Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 17: 144-150, 1997
34. Lopez-Cabrera M, Aguilera A, Aroeira LS, Ramirez-Huesca M, Perez- Lozano ML, Jimenez-Heffernan JA, Bajo MA, del Peso G, Sanchez- Tomero JA, Selgas R: Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure. Perit Dial Int 26: 26-34, 2006
35. Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, Mira E, Iniguez MA, Fresno M, Martinez AC, Arroyo AG, Lopez-Cabrera M: The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane- type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 110: 1831-1838, 2002